Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr Tamoxifen Supply Will Hold To Mid-Nov.; Firm Seeks FDA Injunction

Executive Summary

Barr will be unable to supply tamoxifen 10 mg after mid-November in the absence of court action to overrule FDA and allow the immediate launch of the firm's generic
Advertisement

Related Content

AstraZeneca May Market Unbranded Tamoxifen If Barr Contract Not Resumed
AstraZeneca May Market Unbranded Tamoxifen If Barr Contract Not Resumed
Barr’s Tamoxifen Approval Barred Until Resolution Of ANDA “Deficiencies”
Barr’s Tamoxifen Approval Barred Until Resolution Of ANDA “Deficiencies”
Barr tamoxifen ANDA must wait
Nolvadex Pediatric Exclusivity Extension Would Block Generics Until 2003
Barr/AstraZeneca Tamoxifen Settlement Under Investigation By State AGs
FDA Ordered To Rescind Barr's 180-Day Exclusivity For Generic Tamoxifen
Advertisement
UsernamePublicRestriction

Register

PS040529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel